IP Library › Granted Patent US 9,095,563
Granted Patent B2
US 9,095,563 · App. 14/498,555 · Granted Aug 4, 2015

Topical treatments incorporating

Inventors: Ronald D. Sekura (Key Largo, FL); Roscoe M. Moore, Jr. (Rockville, MD)
A61K31/352A61K31/045A61K31/047A61K31/085A61K31/235A61K31/245A61K31/573A61K36/00A61K36/185A61K36/61
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,095,563
App. No.
14/498,555
Granted
Aug 4, 2015
Kind
B2
Abstract

A topical formulation comprising a Cannabis derived botanical drug product, wherein the concentration of tetrahydrocannabinol, cannabidiol, or both in the topical formulation is greater than 2 milligrams per kilogram.

Claims (33)

1. A topical formulation consisting essentially of an extract of cannabis sativa or cannabis indicia and at least one component selected from the group consisting of capsaicin, benzocaine, lidocaine, camphor, benzoin resin, methylsalicilate, triethanolamine salicylate, hydrocortisone, and salicylic acid, present in an amount of at least 0.1 wt % in the topical formulation, wherein the concentration of tetrahydrocannabinol in the topical formulation is greater than 2 milligrams per kilogram in the topical formulation,

said topical formulation obtained by dispersing the extract of cannabis sativa or cannabis indicia in a water-in-oil emulsion, an oil-in-water emulsion, a wax-in-oil base, or an oil-in-wax base consisting essentially of at least one component selected from the group consisting of capsaicin, benzocaine, lidocaine, camphor, benzoin resin, methylsalicilate, triethanolamine salicylate, hydrocortisone, and salicylic acid.

2. The topical formulation according to claim 1 , wherein said component is capsaicin.

3. The topical formulation according to claim 1 , wherein said component is benzocaine.

4. The topical formulation according to claim 1 , wherein said component is lidocaine.

5. The topical formulation according to claim 1 , wherein said component is camphor.

6. The topical formulation according to claim 1 , wherein said component is benzoin resin.

7. The topical formulation according to claim 1 , wherein said component is methylsalicilate.

8. The topical formulation according to claim 1 , wherein said component is triethanolamine salicylate.

9. The topical formulation according to claim 1 , wherein said component is hydrocortisone.

10. The topical formulation according to claim 1 , wherein said component is salicylic acid.

11. A topical formulation consisting essentially of an extract of cannabis sativa or cannabis indicia and at least one component selected from the group consisting of capsaicin, benzocaine, lidocaine, camphor, benzoin resin, methylsalicilate, triethanolamine salicylate, hydrocortisone, and salicylic acid, present in an amount of at least 0.1 wt % in the topical formulation, wherein the concentration of cannabidiol in the topical formulation is greater than 2 milligrams per kilogram in the topical formulation,

said topical formulation obtained by dispersing the extract of cannabis sativa or cannabis indicia in a water-in-oil emulsion, an oil-in-water emulsion, a wax-in-oil base, or an oil-in-wax base consisting essentially of at least one component selected from the group consisting of capsaicin, benzocaine, lidocaine, camphor, benzoin resin, methylsalicilate, triethanolamine salicylate, hydrocortisone, and salicylic acid.

12. The topical formulation according to claim 11 , wherein said component is capsaicin.

13. The topical formulation according to claim 11 , wherein said component is benzocaine.

14. The topical formulation according to claim 11 , wherein said component is lidocaine.

15. The topical formulation according to claim 11 , wherein said component is camphor.

16. The topical formulation according to claim 11 , wherein said component is benzoin resin.

17. The topical formulation according to claim 11 , wherein said component is methylsalicilate.

18. The topical formulation according to claim 11 , wherein said component is triethanolamine salicylate.

19. The topical formulation according to claim 11 , wherein said component is hydrocortisone.

20. The topical formulation according to claim 11 , wherein said component is salicylic acid.

21. A topical formulation consisting essentially of an extract of cannabis sativa and cannabis indicia and at least one component selected from the group consisting of capsaicin, benzocaine, lidocaine, camphor, benzoin resin, methylsalicilate, triethanolamine salicylate, hydrocortisone, and salicylic acid, present in an amount of at least 0.1 wt % in the topical formulation, wherein the concentration of each of tetrahydrocannabinol and cannabidiol in the topical formulation is greater than 2 milligrams per kilogram in the topical formulation,

said topical formulation obtained by dispersing the extract of cannabis sativa and cannabis indicia in a water-in-oil emulsion, an oil-in-water emulsion, a water in oil emulsion, wax in oil base, or an oil-in-wax base consisting essentially of at least one component selected from the group consisting of capsaicin, benzocaine, lidocaine, camphor, benzoin resin, methylsalicilate, triethanolamine salicylate, hydrocortisone, and salicylic acid.

22. The topical formulation according to claim 21 , wherein said component is capsaicin.

23. The topical formulation according to claim 21 , wherein said component is benzocaine.

24. The topical formulation according to claim 21 , wherein said component is lidocaine.

25. The topical formulation according to claim 21 , wherein said component is camphor.

26. The topical formulation according to claim 21 , wherein said component is benzoin resin.

27. The topical formulation according to claim 21 , wherein said component is methylsalicilate.

28. The topical formulation according to claim 21 , wherein said component is triethanolamine salicylate.

29. The topical formulation according to claim 21 , wherein said component is hydrocortisone.

30. The topical formulation according to claim 21 , wherein said component is salicylic acid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2024
From: SEKURA, RONALD D.; MOORE, ROSCOE M.
To: METRONOME LLC
Reel/Frame 067795/0760 →
Continuity (2)
Provisional Application 61882990 · Sep 26, 2013
Related Publication 20150086494A1 · Mar 26, 2015